3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neuroblastoma
11
Brain Neoplasms
3
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Medulloblastoma
2
Leukemia, Myeloid, Acute
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Xanthomatosis, Cerebrotendinous
1
Vaccinia
1
Uveal Melanoma
1
Transplant-Related Hematologic Malignancy
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Resectable Esophageal Cancer
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Oligodendroglioma
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Influenza, Human
1
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
1 year
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled